Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
NCT04330326 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32
Last updated 2025-02-10
Summary
This short-term, randomized, placebo-controlled, investigator-initiated trial aims to establish metabolic improvements in NAFLD subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine. Concomitant use of pivotal metabolic cofactors via simultaneous dietary supplementation will stimulate three different pathways to enhance hepatic β-oxidation and this study's hypothesis is that this will result in decreased amount of fat in the liver.
Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
Interventions
- DRUG
-
Metabolic Cofactor Supplementation
Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture. Half dosage of the co-factors will be given for two weeks (one dose taken just after dinner), and full dosage for 8 weeks (two equal doses taken just after breakfast and dinner).
- DRUG
-
Sorbitol
As placebo, sorbitol (5 g) flavored with strawberry aroma and coloring agent will be given. Sorbitol is widely used due to its solubility in water. It's approved by the U.S. Food and Drug Administration (FDA).
Sponsors & Collaborators
-
Koç University
collaborator OTHER -
Koç University Hospital
collaborator UNKNOWN -
Göteborg University
collaborator OTHER -
Sahlgrenska University Hospital
collaborator OTHER -
KTH Royal Institute of Technology
collaborator OTHER -
University of Helsinki
collaborator OTHER -
Helsinki University Central Hospital
collaborator OTHER -
Monitor CRO
collaborator INDUSTRY -
ScandiBio Therapeutics AB
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-20
- Primary Completion
- 2020-07-29
- Completion
- 2022-05-06
Countries
- Turkey (Türkiye)
Study Locations
More Related Trials
-
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
NCT04308980 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
NCT07214870 ·Status: RECRUITING ·Phase: PHASE1
-
Probiotic Lysate (Postbiotic and Metabiotic) Supplementation for Adults NAFLD Patients (DELI_NAFLD Study)
NCT05804422 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Nutritional Therapy With High Methionine Content in the Treatment of NAFLD
NCT04450875 ·Status: COMPLETED ·Phase: NA
-
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of Synbiotic Treatment in NAFLD
NCT01680640 ·Status: COMPLETED ·Phase: NA
-
A Study on How Semaglutide Works on Early Stages of Scar Tissue in the Liver Assessed by Pictures of the Liver
NCT03357380 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Trial to Evaluate the Efficacy of Metadoxine as a Therapy for Patients With Non-alcoholic Steatohepatitis
NCT02541045 ·Status: WITHDRAWN ·Phase: PHASE3
-
Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism
NCT04395950 ·Status: WITHDRAWN ·Phase: PHASE1
-
Probiotics in NASH Patients - PROBILIVER TRIAL
NCT03467282 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
NCT04383951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Ketogenic Diet in Non-alcoholic Fatty Liver Disease
NCT03784716 ·Status: COMPLETED ·Phase: NA
-
Semaglutide Effectiveness in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease in the Real World Practice
NCT06983171 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD
NCT03950882 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
NCT06739486 ·Status: NOT_YET_RECRUITING
-
Pilot Study of Ursodesoxycholic Acid in Non-Alcoholic Steatohepatitis
NCT00470171 ·Status: COMPLETED ·Phase: PHASE2
-
Ursodeoxycholic Acid in Patients With NAFLD - Clinical Observation
NCT05256979 ·Status: ACTIVE_NOT_RECRUITING
-
Study in Healthy Adults Evaluating PF-07202954
NCT04857437 ·Status: COMPLETED ·Phase: PHASE1
-
An Follow-Up Study of Liver Cirrhosis
NCT03472742 ·Status: COMPLETED
-
Improving Insulin Resistance To Treat Non-Alcoholic Fatty Liver Disease: A Pilot Study
NCT02457286 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis
NCT04004325 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study To Assess Pharmacodynamics, Safety And Tolerability Of PF-05221304 And PF-06865571 Co-Administered For 6 Weeks In Adults With Non-Alcoholic Fatty Liver Disease.
NCT03776175 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluation of PK and Biomarkers After UDCA Administrations to Subjects Who Are Overweight and Have Liver Problems
NCT03000218 ·Status: UNKNOWN ·Phase: PHASE1
-
Effect of Empagliflozin on Liver Fat in Non-diabetic Patients
NCT04642261 ·Status: COMPLETED ·Phase: PHASE4